EDP Biotech Corporation Release: ColoMarker: Convenient, Low-Cost, Early Stage Colon Cancer Blood Test Reports Validation
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
KNOXVILLE, Tenn.--(BUSINESS WIRE)--EDP Biotech, the US-based developer of a blood test to detect the early stages of colon cancer called ColoMarker™, today announced its plans to commercialize the product and bring the new technology to market. Unlike other diagnostic tests currently in development, the ColoMarker test detects a level of CA11-19 antigen, a specific protein molecule found in the bloodstream. While every human being produces this protein, elevated levels in the bloodstream suggest the presence of colon cancer.
Help employers find you! Check out all the jobs and post your resume.
KNOXVILLE, Tenn.--(BUSINESS WIRE)--EDP Biotech, the US-based developer of a blood test to detect the early stages of colon cancer called ColoMarker™, today announced its plans to commercialize the product and bring the new technology to market. Unlike other diagnostic tests currently in development, the ColoMarker test detects a level of CA11-19 antigen, a specific protein molecule found in the bloodstream. While every human being produces this protein, elevated levels in the bloodstream suggest the presence of colon cancer.
Help employers find you! Check out all the jobs and post your resume.